Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis

Table 2

Selected characteristics in patients with rheumatoid arthritis.

Characteristic	RA; 𝑛=225
Female, 𝑛 (%)	207 (92.0)
Age, years	52.47±10.96
Alcohol consumption*, 𝑛 (%)	28 (12.4)
Smoke exposure, 𝑛 (%)	64 (28.4)
RA characteristics
Disease duration (years), mean ± SD	8.97±8.32
DAS28, mean ± SD	5.04±1.36
HAQ-Di score (units)	0.84±0.67
Global functional status III-IV, 𝑛 (%)	43 (19.1)
Steinbrocker stage in hands III or IV 𝑛 (%)	94 (41.8)
ExRA, 𝑛 (%)	95 (42.2)
Extra-articular manifestations
Sjögren’s Syndrome, 𝑛 (%)	58 (25.8)
Chronic anemia, 𝑛 (%)	33 (14.7)
Rheumatoid nodules, 𝑛 (%)	23 (10.2)
Peripheral neuropathy, 𝑛 (%)	12 (5.3)
Pulmonary fibrosis, 𝑛 (%)	6 (2.7)
Raynaud's phenomenon, 𝑛 (%)	3 (1.3)
Felty’s Syndrome, 𝑛 (%)	2 (0.9)
Thrombosis, 𝑛 (%)	2 (0.9)
Scleritis, 𝑛 (%)	1 (0.4)
Intestinal vasculitis, 𝑛 (%)	1 (0.4)
Laboratory findings
ESR, mm/h	29.22±11.90
CRP, mg/L	20.85±30.83
Positive RF**, 𝑛=204 (%)	135 (66.2)
RF titres, IU/mL	119.11±237.99
Positive anti-CCP	155 (68.9)
Anti-CCP titres, IU/mL	72.44±88.22
Positive anti-MCV	157 (69.7)
Anti-MCV titres, IU/mL	156.85±183.50
(+) anti-CCP and (+) anti-MCV, 𝑛=225	140 (62.2)
(+) anti-CCP, (+) anti-MCV and (+) RF, 𝑛=204	110 (53.9)
Treatment
Synthetic DMARDs, 𝑛 (%)	206 (92.6)
MTX users, 𝑛 (%)	180 (80.0)
Anti-TNFα agents, 𝑛 (%)	19 (8.4)
Corticosteroids, 𝑛 (%)	214 (95.1)
Prednisone (current doses), mg/day	5.24±2.06

RA: rheumatoid arthritis; *Alcohol consumption: defined as consume of at least one alcoholic beverage on a daily basis in the last year. DAS28: disease activity score; HAQ-Di: Health Assessment Questionnaire-Disability Index; ExRA: rheumatoid arthritis with extra-articular manifestations; ESR: erythrocyte sedimentation rate; **RF: rheumatoid factor (only assessed in two thousand four patients); CRP: C-Reactive Protein; anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-MCV: anti-mutated citrullinated vimentin, DMARDs: disease-modifying antirheumatic drugs.
Qualitative variables are expressed as frequencies (%); quantitative variables are expressed as means and standard deviation.